Eunice Wang

0:13:14

The Interconnectedness of Life | Eunice Wang | EcoTraining

0:10:26

Dr. Eunice Wang discusses Secondary MDS

0:05:15

Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

0:02:59

What Should I Do if I Have to Find a New Cancer Treatment Provider?

0:02:08

Types of Leukemia Treatment at Roswell Park

0:02:05

How is Leukemia Diagnosed?

0:04:06

Searching for Effective Treatment in Newly Diagnosed FLT3 Positive AML | Eunice Wang | ASH 2021 #AML

0:01:28

Update on the KOMET-001 trial: ziftomenib in NPM1-mutant AML

0:18:36

Decision-Making in AML: What's Next After Relapse I Dr. Eunice Wang - MRD Status #AML

0:10:55

Eunice Wang, MD, on Treating AML During the COVID-19 Pandemic

0:01:26

The use of olutasidenib in R/R AML: an analysis of outcomes by number of prior treatment regimens

0:01:43

The use of doublets vs triplets for FLT3-mutated AML

0:00:43

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

0:00:31

Dr. Eunice Wang | Spend Just One Day With Us

0:02:26

Dr Ravi Vij MD, is Discussing with Dr. Eunice Wang MD, on Acute Myeloid Leukemia:Targeted Therapies

0:00:55

Eunice S. Wang, MD, discusses the Quantum First Study

0:00:37

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

0:01:13

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

0:02:05

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

0:01:24

Mechanisms of resistance to FLT3 inhibitors in AML and strategies to overcome this

0:01:24

Time to response and OS in patients with IDH1-mutated AML treated with olutasidenib

0:01:30

A Phase I trial investigating a novel oral FLT3 inhibitor, BMF-500, in FLT3-mutant AML

0:02:24

Why Roswell Park for Leukemia Care?

0:01:25

AML Research and Emerging Treatment Options: An Expert’s Perspective